Ultragenyx Pharmaceutical, Inc. (RARE)
15.42
-0.15
(-0.96%)
USD |
NASDAQ |
Nov 06, 16:00
15.42
0.00 (0.00%)
After-Hours: 16:56
Ultragenyx Pharmaceutical Research and Development Expense (Annual) : 723.00M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 723.00M |
| December 31, 2024 | 667.82M |
| December 31, 2023 | 626.24M |
| December 31, 2022 | 690.79M |
| December 31, 2021 | 483.91M |
| December 31, 2020 | 398.68M |
| December 31, 2019 | 357.36M |
| December 31, 2018 | 294.00M |
| Date | Value |
|---|---|
| December 31, 2017 | 231.64M |
| December 31, 2016 | 183.20M |
| December 31, 2015 | 114.74M |
| December 31, 2014 | 45.28M |
| December 31, 2013 | 27.83M |
| December 31, 2012 | 12.64M |
| December 31, 2011 | 4.717M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Ionis Pharmaceuticals, Inc. | 913.18M |
| AbbVie, Inc. | 8.249B |
| Krystal Biotech, Inc. | 52.32M |
| BridgeBio Pharma, Inc. | 451.95M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |